Programmable Bio
Reference Programs
Our flagship reference programs split into two tracks: IVD companion diagnostics, and the full pharma R&D lifecycle.
Reference programs are fully costed, milestone-gated sprints that demonstrate what LabOS + Apollo can deliver. They are the proof points for pharma BD — not slide-deck hypotheticals.
| Track | Timeline | Cost | Best for |
|---|---|---|---|
| IVD Companion Diagnostics | 18 months | $5M vs $30–50M traditional | Pharma with Phase 2 oncology asset needing CDx for Phase 3 stratification |
| Pharma R&D lifecycle | 3–18 months per stage | $0.5M–$3M per program | Target ID through lead optimization, preclinical, clinical (Q3 2026), PV |
Which track?
Choose IVD when the buyer has a drug asset and needs a companion diagnostic. Choose Pharma R&D when the buyer needs discovery infrastructure across the lifecycle — or bundle both when CDx and drug development run in parallel.